Ricardo Macarron has been named president-elect of the Society for Biomolecular Screening, SBS said this week. He is the director of assay development at GlaxoSmithKline in Collegeville, Penn. Maccaron will become president of the society at its April 2007 conference and exhibition inMontreal. He received a PhD in biochemistry and a BS in biological sciences from
Michael Liebman was promoted to executive director of the Windber Research Institute last month, GenomeWeb News has learned. He used to be Windber's chief scientific officer.
Thomas Ingolia has become chief executive officer of Medisyn Technologies, the Minnetonka, Minn.-based company said today. He joins Medisyn from Prolexys Pharmaceuticals, formerly Myriad Proteomics, where he was CEO. Ingolia holds a PhD in biochemistry from the University of California, Berkeley.
David Onions has been promoted to chief medical officer of Invitrogen, a new position, the company said today. He used to be chief scientific officer for BioReliance, a company Invitrogen acquired in 2004. As CMO, Onions will be responsible for guiding Invitrogen's scientific efforts as it moves into areas more closely associated with medical research and closer to patients. He is also a personal chair in veterinary molecular virology at the University of Glasgow. Onions holds a PhD from the University of Cambridge and a BVSc from Bristol University.
John Murphy will resign as executive vice president and chief operating officer of PerkinElmer on Oct. 22, the company said in an SEC filing yesterday. Murphy departs "for personal reasons relating to his decision not to relocate from
Paul Grint has become chief medical officer and head of development of Kalypsys, the San Diego-based company said last week. Prior to joining Kalypsys, he was senior vice president and chief medical officer of Zephyr Sciences. He is also a member of the board of directors of Illumina. Grint holds a medical degree from the University of London, St. Bartholomew's Hospital Medical College.
John Sowatsky has joined NanoString Technologies as vice president of product development, the Seattle-based company said last week. Most recently, he was vice president of the system business unit at Affymetrix.
BioSystems International has appointed a scientific advisory board, the Evry, France-based biomarker company said last week. Members of the board are Laszlo Fesus of the University of Debrecen Medical and Health Science Center in Hungary; Andras Guttman of the University of Innsbruck, Austria; William Hancock of Northeastern University; Barry Karger of Northeastern University; Edward Rubin of Lawrence Berkeley National Laboratory Berkeley; Laszlo Takacs, president and CSO of BioSystems International; Jean Paul Thiery of the Institut Curie in Paris; and Peter Zavodszky of Eotvos Lorand University in Budapest.
Michael Hunkapiller has been appointed to the board of directors of Fluidigm, the company said on Monday. The appointment coincides with an investment by Alloy Ventures, the investment capital firm Hunkapiller joined in 2004. Prior to that, he was general manager and president of Applied Biosystems. He holds a PhD in chemical biology from Caltech and a BS in chemistry from Oklahoma Baptist University.
Ian Humphery-Smith has been chief executive officer of the Biosystems Informatics Institute and its commercial trading arm, Turbinia, both of Newcastle-upon-Tyne, UK, since last December, GenomeWeb News has learned. Since he left his post as COO of Glaucus Proteomics, which went out of business three years ago, he has been a consultant to the biotechnology industry. Humphery-Smith holds a PhD and a BSc in parasitology and infectious diseases from the University of Queensland,